19th Canadian Melanoma Conference 2025: Merck Breakfast Symposium: When to Consider Adjuvant Immunotherapy in the Treatment of Stage II-III Melanoma – Dr. Carolyn Nessim, Dr. Elaine McWhirter, Enzo Federico
OR
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Merck
